Quick Answer
Organogenesis Holdings Inc. reported Gross Profit of $366.30 million for the year ending 2024.
- Organogenesis Holdings Inc. showed an increase of +12.1% in Gross Profit from 2023 to 2024.
- This data is from Organogenesis Holdings Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2025.
- XBRL data for this metric is available from 2016 to 2024 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $26.53 million | Q2 2017: $38.67 million | Q3 2017: $35.37 million | Q4 2017: $36.72 million | Q1 2018: $21.01 million | Q2 2018: $26.25 million | Q3 2018: $31.29 million | Q4 2018: $46.09 million | Q1 2019: $40.14 million | Q2 2019: $45.50 million | Q3 2019: $45.13 million | Q1 2020: $42.94 million | Q2 2020: $48.92 million | Q3 2020: $77.84 million | Q1 2021: $77.06 million | Q2 2021: $93.26 million | Q3 2021: $87.59 million | Q1 2022: $72.04 million | Q2 2022: $94.75 million | Q3 2022: $90.68 million | Q1 2023: $81.04 million | Q2 2023: $91.00 million | Q3 2023: $82.74 million | Q1 2024: $81.28 million | Q2 2024: $101.04 million | Q3 2024: $88.38 million | Q1 2025: $62.97 million.
- Over the full 9 years of available data (2016 to 2024), Organogenesis Holdings Inc.'s Gross Profit has grown by 304.6%.
- Historical annual values: Fiscal year 2024: $366.30 million | Fiscal year 2023: $326.66 million | Fiscal year 2022: $345.87 million | Fiscal year 2021: $353.16 million | Fiscal year 2020: $250.98 million | Fiscal year 2019: $185.03 million | Fiscal year 2018: $124.64 million | Fiscal year 2017: $137.29 million | Fiscal year 2016: $90.53 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: